Navigation Links
InspireMD to Ring Opening Bell at New York Stock Exchange on Thursday, October 24th
Date:10/23/2013

BOSTON, Oct. 23, 2013 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will ring the Opening Bell at the New York Stock Exchange on Thursday, October 24, 2013 at 9:30 a.m. ET.

Representing the Company, Alan Milinazzo, Chief Executive Officer, and Craig Shore, Chief Financial Officer, will be joined by members of the InspireMD management team to ring the Opening Bell.

"We look forward to ringing the Opening Bell at the New York Stock Exchange as we celebrate the progress made by the Company over the past year," said Alan Milinazzo, Chief Executive Officer of InspireMD.  "Over the next year, we are looking forward to several exciting milestones within our clinical and product development programs, as well as for our commercialization operations.  This includes the announcement next week of 12-month follow-up data for the MASTER trial in San Francisco at the Transcatheter Cardiovascular Therapeutics (TCT) Conference on October 29th."

A live webcast of the NYSE Opening Bell Ceremony will be available online at:
https://nyse.nyx.com/the-bell/todays-bells-live.

A replay of the NYSE Opening Bell Ceremony and photos from the event will be available at:
www.Inspire-MD.com or https://exchanges.nyx.com/new-york-stock-exchange-0.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuard™ technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures.  InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard™ EPS is CE Mark approved. It is not approved for sale in the U.S. by the FDA at this time.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com

Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: 212-896-1216 / 212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com


'/>"/>
SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
2. InspireMD Appoints David Blossom as Vice President of Global Marketing and Strategy
3. InspireMD Announces Participation in Two Investor Conferences in September
4. InspireMD Completes First Phase of Manufacturing Upgrade and Partners with HealthLink for Global Logistics and Distribution Services
5. InspireMDs MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
6. InspireMD Reports Financial Results For Period Ended March 31, 2013
7. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
8. InspireMD Closes $25 Million Underwritten Public Offering
9. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
10. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
11. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Global Immunology ... market to drive long-term market growth Summary ... set of chronic disorders that affect 5–7% of ... terms of their symptoms and key patient demographics, ... of immune pathways and an inappropriate immune response. ...
(Date:2/4/2016)... VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... management solutions to healthcare systems, today announced results for ... --> --> GAAP ... $130.3 million, up $5.1 million or 4.1% from the ... 7.2% from the fourth quarter of 2014. Revenue for ...
(Date:2/4/2016)... SAN DIEGO, Feb. 4, 2016  Aethlon Medical, ... creating affinity biofiltration devices to treat life-threatening diseases, ... fiscal 2016 ended December 31, 2015. ... short-term objectives set forth in our last quarterly ... that reinforce our long-term objective to establish the ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter ... gathered at the La Valencia Hotel in San Diego, California to discuss changes ... the year’s most outstanding franchise, walking away with the coveted David Wright Award ...
(Date:2/5/2016)... ... 2016 , ... Pivot Point Consulting, a leading national Healthcare ... Services for HIT Implementation Support & Staffing report with an outstanding score of ... healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. , ...
(Date:2/5/2016)... Aliso Viejo, CA (PRWEB) , ... February 05, 2016 , ... ... Pro X. Move from on one drop zone to the next using Colorize's dynamic ... design complements any project. This package includes a 3D slideshow environment with 1 to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Calls Blacklist has just ... new user interface design and the developer has fixed known bugs within the app. ... to on their phone while not consuming any of their device’s battery power or ...
(Date:2/4/2016)... ... February 04, 2016 , ... Dr. Carol Francis and ... February 19-21, 2016, in Southern California . The International Hypnosis Federation 2016 Conference ... professional speakers, including Clinical Psychologist and Hypnotherapist Dr. Carol Francis (topics ...
Breaking Medicine News(10 mins):